Quest Diagnostics
DGX
1,005 hedge funds and large institutions have $20B invested in Quest Diagnostics in 2025 Q3 according to their latest regulatory filings, with 114 funds opening new positions, 358 increasing their positions, 343 reducing their positions, and 82 closing their positions.
39% more first-time investments, than exits
New positions opened: 114 | Existing positions closed: 82
2% more funds holding
Funds holding: 990 → 1,005 (+15)
4% more repeat investments, than reductions
Existing positions increased: 358 | Existing positions reduced: 343
4% more capital invested
Capital invested by funds: $19.3B → $20B (+$680M)
2.39% less ownership
Funds ownership: 96.25% → 93.86% (-2.4%)
12% less call options, than puts
Call options by funds: $98.2M | Put options by funds: $112M
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
+$177M |
| 2 |
EIG
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
+$151M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$77M |
| 4 |
Goldman Sachs
New York
|
+$74.2M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$62.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$108M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$82.6M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$73.8M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$55.9M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$55.8M |
DGX Hedge Fund Activity: Q3 2025 in Review
1,005 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q3 2025, worth a combined $20B — up 3.5% from $19.3B a quarter earlier.
Buyers outnumbered sellers: 114 funds opened new DGX positions and 82 closed out — a net gain of 32 holders — while 358 added to existing stakes and 343 trimmed.
The largest buyer was Boston Partners, adding an estimated $177M. The largest seller was AllianceBernstein, cutting an estimated $108M.
- 1,005 institutional investors held Quest Diagnostics (DGX) as of Q3 2025, up from 990 in Q2 2025.
- Funds reported $20B of Quest Diagnostics stock for Q3 2025, up 3.5% quarter-over-quarter.
- 114 funds opened new Quest Diagnostics positions in Q3 2025 and 82 closed out, a net change of +32 holders.
- The largest Quest Diagnostics buyer in Q3 2025 was Boston Partners, an estimated $177M added.
- The largest Quest Diagnostics seller in Q3 2025 was AllianceBernstein, an estimated $108M sold.
Based on aggregated 13F filings for Q3 2025.